BR112023018330A2 - Métodos para predição de resposta ao tratamento em colite ulcerativa - Google Patents

Métodos para predição de resposta ao tratamento em colite ulcerativa

Info

Publication number
BR112023018330A2
BR112023018330A2 BR112023018330A BR112023018330A BR112023018330A2 BR 112023018330 A2 BR112023018330 A2 BR 112023018330A2 BR 112023018330 A BR112023018330 A BR 112023018330A BR 112023018330 A BR112023018330 A BR 112023018330A BR 112023018330 A2 BR112023018330 A2 BR 112023018330A2
Authority
BR
Brazil
Prior art keywords
inflammatory bowel
treatment
bowel disease
methods
ulcerative colitis
Prior art date
Application number
BR112023018330A
Other languages
English (en)
Inventor
Feifei Yang
Xilin Li
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112023018330A2 publication Critical patent/BR112023018330A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

métodos para predição de resposta ao tratamento em colite ulcerativa. a presente invenção refere-se a biomarcadores que podem ser usados para a detecção ou diagnóstico de estados doentios, de preferência estados de doença inflamatória intestinal, a identificação de um regime de tratamento de doença inflamatória intestinal e/ou para indicar a capacidade de resposta ao regime de tratamento de doença inflamatória intestinal em um indivíduo. são descritas também sondas capazes de detectar os biomarcadores e métodos e kits relacionados para determinar estados de doença inflamatória intestinal e/ou identificação de regimes de tratamento para os estados de doença inflamatória intestinal.
BR112023018330A 2021-03-12 2022-03-10 Métodos para predição de resposta ao tratamento em colite ulcerativa BR112023018330A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163160199P 2021-03-12 2021-03-12
PCT/IB2022/052166 WO2022190036A2 (en) 2021-03-12 2022-03-10 Methods for predicting treatment response in ulcerative colitis

Publications (1)

Publication Number Publication Date
BR112023018330A2 true BR112023018330A2 (pt) 2023-12-05

Family

ID=80786892

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018330A BR112023018330A2 (pt) 2021-03-12 2022-03-10 Métodos para predição de resposta ao tratamento em colite ulcerativa

Country Status (10)

Country Link
US (1) US20220291238A1 (pt)
EP (1) EP4305425A2 (pt)
JP (1) JP2024509953A (pt)
KR (1) KR20230156746A (pt)
CN (1) CN117295952A (pt)
AU (1) AU2022233979A1 (pt)
BR (1) BR112023018330A2 (pt)
CA (1) CA3213280A1 (pt)
IL (1) IL305808A (pt)
WO (1) WO2022190036A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117554614A (zh) * 2022-09-23 2024-02-13 上海市第十人民医院 蛋白生物标志物dpp4在克罗恩病临床诊断中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028044A2 (en) * 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
US7875431B2 (en) * 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP3196210A1 (en) * 2011-11-23 2017-07-26 Amgen, Inc Methods of treatment using an antibody against interferon gamma
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
WO2020104705A2 (en) * 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
CA3121167A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
CN110174513A (zh) * 2019-04-15 2019-08-27 中山大学附属第一医院 Tgm2在制备监测克罗恩病疾病活动的生物标志物中的应用
EP4015651A1 (en) * 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients

Also Published As

Publication number Publication date
AU2022233979A1 (en) 2023-10-26
WO2022190036A2 (en) 2022-09-15
CN117295952A (zh) 2023-12-26
CA3213280A1 (en) 2022-09-15
IL305808A (en) 2023-11-01
EP4305425A2 (en) 2024-01-17
WO2022190036A3 (en) 2022-10-20
US20220291238A1 (en) 2022-09-15
AU2022233979A9 (en) 2023-11-02
KR20230156746A (ko) 2023-11-14
JP2024509953A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
BR112022019754A2 (pt) Ensaios para detecção de sars-cov-2
Penny et al. Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts
Sipponen et al. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease
Leligdowicz et al. Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection
Swale et al. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study
BR112022019764A2 (pt) Ensaios para detecção de sars-cov-2
RU2018142294A (ru) Усовершенствованное устройство и способ тестирования на беременность
Trembling et al. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
Liu et al. Evaluation of droplet digital PCR for quantification of SARS-CoV-2 Virus in discharged COVID-19 patients
BR112023018330A2 (pt) Métodos para predição de resposta ao tratamento em colite ulcerativa
BR112018073178A2 (pt) método, matriz e uso dos mesmos
Reddy et al. Molecular epidemiology of rifampicin resistance in Mycobacterium tuberculosis using the GeneXpert MTB/RIF assay from a rural setting in India
Shim et al. Diagnostic value of the Vesikari Scoring System for predicting the viral or bacterial pathogens in pediatric gastroenteritis
Zheng et al. Prognostic value of circulating tumor cells in castration resistant prostate cancer: a meta-analysis
Pang et al. Discovery and validation of prognostic biomarker models to guide triage among adult dengue patients at early infection
BR112023015956A2 (pt) Dispositivo para examinar um alvo, sistema para examinar um alvo, dispositivo para treinar um modelo de análise para analisar imagens de alvos com base em fluorescência, método para examinar um alvo e método para treinar um modelo de análise para analisar imagens com base em fluorescência de alvos
Lee et al. Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
Hosseini et al. Fecal calprotectin is an accurate tool and correlated to seo index in prediction of relapse in iranian patients with ulcerative colitis
Ahn et al. Efficacy of stool multiplex polymerase chain reaction assay in adult patients with acute infectious diarrhea
Landewé Predictive markers in rapidly progressing rheumatoid arthritis.
EA202191354A1 (ru) Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
Li et al. Determining procalcitonin at point-of-care; A method comparison study of four commercial PCT assays
Näsström et al. Reproducible diagnostic metabolites in plasma from typhoid fever patients in Asia and Africa
BR112012008336A2 (pt) sondas de ácido nucleico peptídico, kit e método para detectar helicobacter pylori e / ou perfil de resistência à claritromicina e aplicações